Company profile
UK company 13972139, incorporated on 11 March 2022.
Bot Verification
Isomab Ltd is a UK company with status active founded in 2022 based in East of England.
Company number 13972139
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
AA | Transaction MzU0MzE0MDExOGFkaXF6a2N4
Published 08 Sep 2026 14:13
Company registered at Companies House
IsomAb develops isoform specific antibodies.
IsomAb is developing isoform specific, humanised IgG1 based antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, its first antibody against Vascular Endothelial Growth Factor A (VEGF-A). Our strategy utilises an antibody to specifically inhibit the VEGF-A165b isoforms; based on 20 years of research, the evidence shows this isoform is key to preventing collateral vessel formation in ischemic diseases.
IsomAb is a pre-clinical stage company with Proof-of-Concept data, in two animal models, and an ambitious plan to take its first product into the clinic by 2026.
